Диссертация (1141269), страница 14
Текст из файла (страница 14)
Медведев Ю.В., Раменская Г.В., Шохин И.Е., Ярушок Т.А. ВЭЖХ иСВЭЖХ как методы для определения лекарственных веществ в крови(обзор) // Химико-фармацевтический журнал, Т. 47, № 4, 2013. С. 45-51.62. Roux A., Lison D., Junot C., Heilier J.F. Applications of liquid chromatographycoupled to mass spectrometry-based metabolomics in clinical chemistry andtoxicology: A review // Clinical Biochemistry, Vol. 44, No.
1, 2011. pp. 119–135.63. Marquet P. Progress of Liquid Chromatography–Mass Spectrometry in Clinicaland Forensic Toxicology // Therapeutic Drug Monitoring, Vol. 24, No. 2, 2002.pp. 255-276.64. Pelander A., Ojanperä I., Laks S., Rasanen I., Vuori E. Toxicological ScreeningwithFormula-BasedMetaboliteIdentificationbyLiquidChromatography/Time-of-Flight Mass Spectrometry // Anal Chem, Vol. 75,107No.
21, 2003. pp. 5710–5718.65. Maurer H.H. Multi-analyte procedures for screening for and quantification ofdrugs in blood, plasma, or serum by liquid chromatography-single stage ortandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical andforensic toxicology // Clinical Biochemistry, Vol. 38, No. 4, 2005. pp. 310–318.66.
Maurer H.H. Current role of liquid chromatography–mass spectrometry inclinical and forensic toxicology // Analytical and Bioanalytical Chemistry, Vol.388, No. 7, 2007. pp. 1315-1325.67. Wu A.H., Gerona R., Armenian P., French D., Petrie M., Lynch K.L. Role ofliquid chromatography–high-resolution mass spectrometry (LC-HR/MS) inclinical toxicology // Clinical Toxicology, Vol.
50, No. 8, 202. pp. 733-742.68. Gaillard Y., Pépin G. Use of high-performance liquid chromatography withphotodiode-array UV detection for the creation of a 600-compound libraryapplication to forensic toxicology // Journal of Chromatography A, Vol. 763,No. 1-2, 1997. pp. 149–163.69. Humbert L., Grisel F., Richeval C., Lhermitte M. Screening of Xenobiotics byUltra-Performance Liquid Chromatography-Mass Spectrometry Using InSource Fragmentation at Increasing Cone Voltages: Library Constitution and anEvaluation of Spectral Stability // J Anal Toxicol, Vol.
34, No. 9, 2010. pp.571-580.70. Venisse N., Marquet P., Duchoslav E., Dupuy J.L., Lachâtre G. A generalunknown screening procedure for drugs and toxic compounds in serum usingliquid chromatography-electrospray-single quadrupole mass spectrometry //Journal of Analytical Toxicology, Vol. 27, No. 1, 2003. pp. 7-14.71.
Peters F.T. Recent advances of liquid chromatography–(tandem) massspectrometry in clinical and forensic toxicology // Clinical Biochemistry, Vol.44, No. 1, 2011. pp. 54–65.10872. Remane D., Wetzel D., Peters F.T. Development and validation of a liquidchromatography-tandem mass spectrometry (LC-MS/MS) procedure forscreening of urine specimens for 100 analytes relevant in drug-facilitated crime(DFC) // Analytical and Bioanalytical Chemistry, Vol.
406, No. 18, 2014. pp.4411-4424.73. Smyth W.F. Recent studies on the electrospray ionisation mass spectrometricbehaviour of selected nitrogen-containing drug molecules and its application todrug analysis using liquid chromatography–electrospray ionisation massspectrometry // J. Chromatogr. B, Vol. 824, No. 1-2, 2005.
pp. 1-20.74. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performanceliquid chromatography–electrospray–tandem mass spectrometry // ClinicalBiochemistry, Vol. 38, No. 4, 2005. pp. 328–334.75. Peters F.T., Remane D. Aspects of matrix effects in applications of liquidchromatography–mass spectrometry to forensic and clinical toxicology—areview // Analytical and Bioanalytical Chemistry, Vol.
403, No. 8, 2012. pp.2155-2172.76. Dams R., Huestis M.A., Lambert W.E., Murphy C.E. Matrix effect in bioanalysis of illicit drugs with LC-MS/MS: influence of ionization type, samplepreparation, and biofluid // Journal of the American Society for MassSpectrometry, Vol. 14, No. 11, 2003.
pp. 1290–1294.77. Shen J.X., Motyka R.J., Roach J.P., Hayes R.N. Minimization of ionsuppression in LC–MS/MS analysis through the application of strong cationexchange solid-phase extraction (SCX-SPE) // Journal of Pharmaceutical andBiomedical Analysis, Vol. 37, No. 2, 2005. pp. 359–367.78. Kneisel S., Auwärter V. Analysis of 30 synthetic cannabinoids in serum byliquid chromatography-electrospray ionization tandem mass spectrometry afterliquid-liquid extraction // Journal of Mass Spectrometry, Vol.
47, No. 7, 2012.pp. 825–835.10979. Lee H.K., Ho C.S., Iu Y.P., Lai P.S., Shek C.C., Lo Y.C., Klinke H.B., WoodM. Development of a broad toxicological screening technique for urine usingultra-performance liquid chromatography and time-of-flight mass spectrometry// Analytica Chimica Acta, Vol. 649, No. 1, 2009. pp. 80–90.80. Naidong W., Bu H., Chen Y.L., Shou W.Z., Jiang X., Halls T.D. Simultaneousdevelopment of six LC-MS-MS methods for the determination of multipleanalytes in human plasma // Journal of Pharmaceutical and BiomedicalAnalysis, Vol.
28, No. 6, 2002. pp. 1115–1126.81. Kolmonen M., Leinonen A., Pelander A., Ojanperä I. A general screeningmethod for doping agents in human urine by solid phase extraction and liquidchromatography/time-of-flight mass spectrometry // Analytica Chimica Acta,Vol. 585, No. 1, 2007. pp. 94–102.82. Pragst F. Application of solid-phase microextraction in analytical toxicology //Analytical and Bioanalytical Chemistry, Vol. 388, No. 7, 2007.
pp. 1393-1414.83. Bourgogne E., Grivet C., Varesio E., Hopfgartner G. Generic on-line solidphase extraction sample preparation strategies for the analysis of drugs inbiological matrices by LC–MS/MS // Journal of Pharmaceutical andBiomedical Analysis, Vol. 102, No. 5, 2015. pp. 290–298.84. Pedersen A.J., Dalsgaard P.W., Rode A.J., Rasmussen B.S., Müller I.B.,Johansen S.S., Linnet K. Screening for illicit and medicinal drugs in wholeblood using fully automated SPE and ultra-high-performance liquidchromatography with TOF-MS with data-independent acquisition // J. Sep.Science, Vol.
36, No. 13, 2013. pp. 2081–2089.85. Dams R., Murphy C.M., Choo R.E., Lambert W.E., De Leenheer A.P., HuestisM.A. LC-atmospheric pressure chemical ionization-MS/ MS analysis ofmultiple illicit drugs, methadone, and their metabolites in oral fluid followingprotein precipitation // Anal. Chem., Vol. 75, No. 4, 2003. pp. 798–804.86. Li H., Wang Y., Jiang Y., Tang Y., Wang J., Zhao L., Gu J. A liquid110chromatography/tandem mass spectrometry method for the simultaneousquantification of valsartan and hydrochlorothiazide in human plasma // Journalof Chromatography B, Vol.
852, No. 1-2, 2007. pp. 436–442.87. Souverain S., Rudaz S., Veuthey J.L. Protein precipitation for the analysis of adrug cocktail in plasma by LC–ESI–MS // Journal of Pharmaceutical andBiomedical Analysis, Vol. 35, No. 4, 2004. pp. 913–920.88. Ma J., Shi J., Le H., Cho R., Huang J.C., Miao S., Wong B.K. A fullyautomated plasma protein precipitation sample preparation method for LCMS/MS bioanalysis // Journal of Chromatography B, Vol. 862, No.
1-2, 2008.pp. 219–226.89. Polson C., Sarkar P., Incledon B., Raguvaran V., Grant R. Optimization ofprotein precipitation based upon effectiveness of protein removal and ionizationeffect in liquid chromatography-tandem mass spectrometry // Journal ofChromatography B, Vol. 785, No. 2, 2003. pp. 263–275.90. Яшин Я.И., Яшин Е.Я., Яшин А.Я.
Газовая хроматография. М.: ТрансЛит,2009. 528 с.91. Demme U., Arndt C., Dorn M., Werner R. Application of Two-DimensionalHigh-Performance Thin-Layer Chromatography to Qualitative and QuantitativeToxicological–Chemical Analysis // Journal of Planar Chromatography, Vol.27, No. 4, 2014. pp. 299–314.92. Gonzalez O., Iriarte G., Rico E., Ferreirós N., Maguregui M.I., Alonso R.M.,Jiménez R.M. LC–MS/MS method for the determination of several drugs usedin combined cardiovascular therapy in human plasma // Journal ofChromatography B, Vol. 278, No. 28, 2010.
pp. 2685–2692.93. Kristoffersen L., Øiestad E.L., Opdal M.S., Krogh M., Lundanes E.,Christophersen A.S. Simultaneous determination of 6 beta-blockers, 3 calciumchannel antagonists, 4 angiotensin-II antagonists and 1 antiarrhythmic drug inpost-mortem whole blood by automated solid phase extraction and liquid111chromatography mass spectrometry // J Chromatogr B, Vol. 850, No. 1-2,2007. pp. 147-160.94. Gonzalez O., Alonso R.M., Ferreirós N., Weinmann W., Zimmermann R.,Dresen S.
Development of an LC-MS/MS method for the quantitation of 55compounds prescribed in combined cardiovascular therapy // Journal ofChromatography B, Vol. 879, No. 3-4, 2011. pp. 243-252.95. Gu Q., Chen X., Zhong D., Wang Y. Simultaneous determination of enalapriland enalaprilat in human plasma by liquid chromatography-tandem massspectrometry // Journal of Chromatography B, Vol. 813, No. 1-2, 2004.
pp.337–342.96. Dias E., Hachey B., McNaughton C., Nian H., Yu C., Straka B., Brown N.J.,Caprioli R.M. An LC-MS assay for the screening of cardiovascular medicationsin human samples // Journal of Chromatography B, Vol. 937, 2013. pp. 44–53.97. Lu S., Jiang K., Qin F., Lu X., Li F. Simultaneous quantification of enalapriland enalaprilat in human plasma by high-performance liquid chromatography–tandem mass spectrometry and its application in a pharmacokinetic study //Journal of Pharmaceutical and Biomedical Analysis, Vol. 49, No. 1, 2009. pp.163–167.98. Cheregi M., Albu F., Udrescu S., Răducanu N., Medvedovici A.
Greenerbioanalytical approach for LC/MS-MS assay of enalapril and enalaprilat inhuman plasma with total replacement of acetonitrile throughout all analyticalstages // Journal of Chromatography B, Vol. 927, 2013. pp. 124–132.99. Lee J., Son J., Lee M., Lee K.T., Kim D.H. Simultaneous quantitation ofenalapril and enalaprilat in human plasma by 96-well solid-phase extractionandliquidchromatography/tandemmassspectrometry//RapidCommunications in Mass Spectrometry, Vol.